NVCR N Stock Overview An oncology company, engages in the development, manufacture, and commercialization of tumor treating fields (TTFields) devices for the treatment of solid tumor cancers in the United States, Germany, Japan, Greater China, and internationally. More details
Rewards Risk Analysis See All Risk Checks Capture your thoughts, links and company narrative
NovoCure Limited Competitors Price History & Performance
Summary of share price highs, lows and changes for NovoCure Historical stock prices Current Share Price US$275.39 52 Week High US$2,140.47 52 Week Low US$275.39 Beta 0.52 1 Month Change 0% 3 Month Change n/a 1 Year Change n/a 3 Year Change n/a 5 Year Change n/a Change since IPO -86.68%
Recent News & Updates
Zai Lab and Novocure Announce Positive Topline Results from Phase 3 PANOVA-3 Clinical Trial of Tumor Treating Fields (TTFields) Therapy for Pancreatic Cancer Dec 03
Novocure FDA Approves Novocure’S Innovative HFE Transducer Arrays for Use with Optune Gio® for Glioblastoma Nov 21 NovoCure Limited Appoints Christoph Brackmann as Senior Financial Advisor
FDA Approves Novocure's Optune Lua® for the Treatment of Metastatic Non-Small Cell Lung Cancer Oct 16
NovoCure Limited to Report Q3, 2024 Results on Oct 30, 2024 Oct 01 Novocure Announces CEO Changes, Effective January 1, 2025 See more updates
Zai Lab and Novocure Announce Positive Topline Results from Phase 3 PANOVA-3 Clinical Trial of Tumor Treating Fields (TTFields) Therapy for Pancreatic Cancer Dec 03
Novocure FDA Approves Novocure’S Innovative HFE Transducer Arrays for Use with Optune Gio® for Glioblastoma Nov 21 NovoCure Limited Appoints Christoph Brackmann as Senior Financial Advisor
FDA Approves Novocure's Optune Lua® for the Treatment of Metastatic Non-Small Cell Lung Cancer Oct 16
NovoCure Limited to Report Q3, 2024 Results on Oct 30, 2024 Oct 01 Novocure Announces CEO Changes, Effective January 1, 2025
NovoCure Limited(NasdaqGS:NVCR) dropped from Russell 1000 Dynamic Index Jul 03
NovoCure Limited to Report Q2, 2024 Results on Jul 25, 2024 Jul 02
Novocure Announces the Presentation of Clinical Data from the Phase 3 Metis Trial Jun 05
Novocure Releases Topline Efficacy and Safety Data from the TIGER Study Investigating the Use of Tumor Treating Fields Therapy in the Treatment of Patients with Newly Diagnosed Glioblastoma in Germany May 24 NovoCure Limited announced that it expects to receive $400 million in funding May 03
NovoCure Limited Announces Results of the Metis Phase 3 Clinical Trial in Brain Metastases from Non-Small Cell Lung Cancer Apr 25
NovoCure Limited, Annual General Meeting, Jun 05, 2024 Apr 23
NovoCure Limited to Report Q1, 2024 Results on May 02, 2024 Apr 02
Novocure Announces FDA Acceptance of the PMA Application for TTFields Therapy in Non-Small Cell Lung Cancer Jan 18
NovoCure Limited Announces Last Patient Enrolled in Phase 3 Trident Trial in Newly Diagnosed Glioblastoma Jan 09 NovoCure Limited Announces Executive Changes Novocure Announces Portfolio Prioritization and Strategic Restructuring Plan Focused on Near-Term Growth Drivers and an Accelerated Path to Profitability Nov 29
NovoCure Limited to Report Q3, 2023 Results on Oct 26, 2023 Oct 05
NovoCure Limited(NasdaqGS:NVCR) dropped from FTSE All-World Index (USD) Sep 18
Novocure Announces the Lancet Oncology Publishes Primary Data from Phase 3 Lunar Clinical Trial in Patients with Metastatic Non-Small Cell Lung Cancer After Platinum-Based Therapies Aug 30
Levi & Korsinsky Notifies NovoCure Limited Investors of a Class Action Lawsuit and Upcoming Deadline Aug 05
Chief Financial Officer recently sold Mex$589k worth of stock Aug 05
Second quarter 2023 earnings released: US$0.54 loss per share (vs US$0.23 loss in 2Q 2022) Aug 02 Novocure Announces Favorable Independent Data Monitoring Committee Recommendation to Continue Phase 3 Panova-3 Clinical Trial of Tumor Treating Fields Therapy in Pancreatic Cancer Jul 23
NovoCure Limited to Report Q2, 2023 Results on Jul 27, 2023 Jul 04
Holzer & Holzer, LLC Files Lawsuit Against NovoCure Limited Jun 21 Zai Lab and Novocure Announces Lunar Phase 3 Clinical Trial Demonstrates Statistically Significant and Clinically Meaningful Extension in Overall Survival for Patients with Metastatic Non-Small Cell Lung Cancer After Platinum-Based Therapies Jun 07
Chief Operating Officer recently sold Mex$35m worth of stock Mar 10
Chief Human Resources Officer recently sold Mex$383k worth of stock Mar 07
Full year 2022 earnings released: US$0.88 loss per share (vs US$0.56 loss in FY 2021) Feb 24
Insufficient new directors Feb 17
Novocure Announces Last Patient Enrolled in Pivotal PANOVA-3 Study of Tumor Treating Fields in Pancreatic Cancer Feb 16
Novocure Announces Executive Changes Jan 20 Zai Lab Limited and Novocure Announce Pivotal Lunar Study in Non-Small Cell Lung Cancer Met Primary Overall Survival Endpoint
Insufficient new directors Jan 05
Insufficient new directors Nov 18
Third quarter 2022 earnings released: US$0.25 loss per share (vs US$0.13 loss in 3Q 2021) Oct 27
Insufficient new directors Oct 24
Novocure Announces 11 Presentations on Tumor Treating Fields in Multiple Solid Tumor Types at the American Society for Radiation Oncology 2022 Annual Meeting Oct 22
NovoCure Limited to Report Q3, 2022 Results on Oct 27, 2022 Oct 04
Insufficient new directors Sep 19
Executive Chairman recently sold Mex$1.2m worth of stock Aug 04
Second quarter 2022 earnings released: US$0.23 loss per share (vs US$0.14 loss in 2Q 2021) Jul 28
Insufficient new directors Jul 18
NovoCure Limited to Report Q2, 2022 Results on Jul 28, 2022 Jul 02
Novocure Enrolls First Patient in KEYNOTE-B36, a Pilot Study of Tumor Treating Fields Together with KEYTRUDA® for Patients with First-Line Stage III Non-Small Cell Lung Cancer Jun 22
Novocure and Zai Lab Announce EF-31 Phase 2 Pilot Study Evaluating Tumor Treating Fields Together with Standard-of-Care Chemotherapy Meets Primary Endpoint for First-Line Treatment of Gastric Cancer Jun 04
Now 20% undervalued after recent price drop May 31
Chief Medical Officer recently sold Mex$5.4m worth of stock May 14
Insufficient new directors May 12 NovoCure Limited, Annual General Meeting, Jun 08, 2022
NovoCure Limited to Report Q1, 2022 Results on Apr 28, 2022 Apr 02
General Counsel recently sold Mex$4.6m worth of stock Mar 09
Insufficient new directors Mar 02 Novocure Announces Resignation of Todd Longsworth as General Counsel
Insufficient new directors Jan 27
President recently bought Mex$11m worth of stock Dec 01
Insufficient new directors Dec 01
NovoCure Limited Announces Last Patient Enrolled in Phase 3 Pivotal LUNAR Trial of Tumor Treating Fields in Non-small Cell Lung Cancer Nov 24 Shareholder Returns NVCR N MX Medical Equipment MX Market 7D 0% 0% 0% 1Y n/a 0% 0%
See full shareholder returns
Return vs Market: Insufficient data to determine how NVCR N performed against the MX Market .
Price Volatility Is NVCR N's price volatile compared to industry and market? NVCR N volatility NVCR N Average Weekly Movement n/a Medical Equipment Industry Average Movement 0% Market Average Movement 0% 10% most volatile stocks in MX Market 0% 10% least volatile stocks in MX Market 0%
Stable Share Price: NVCR N has not had significant price volatility in the past 3 months.
Volatility Over Time: Insufficient data to determine NVCR N's volatility change over the past year.
About the Company NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of tumor treating fields (TTFields) devices for the treatment of solid tumor cancers in the United States, Europe, the Middle East, Africa, Japan, and Greater China. Its TTFields devices include Optune for the treatment of glioblastoma; and Optune Lua for the treatment of malignant pleural mesothelioma. The company also has ongoing or completed clinical trials investigating TTFields in brain metastases, gastric cancer, glioblastoma, liver cancer, non-small cell lung cancer, pancreatic cancer, and ovarian cancer.
Show more NovoCure Limited Fundamentals Summary How do NovoCure's earnings and revenue compare to its market cap? NVCR N fundamental statistics Market cap Mex$27.09b Earnings (TTM ) -Mex$3.35b Revenue (TTM ) Mex$8.56b
Earnings & Revenue Key profitability statistics from the latest earnings report (TTM) NVCR N income statement (TTM ) Revenue US$503.98m Cost of Revenue US$124.00m Gross Profit US$379.98m Other Expenses US$577.25m Earnings -US$197.27m
Last Reported Earnings
Sep 30, 2023
Earnings per share (EPS) -1.85 Gross Margin 75.40% Net Profit Margin -39.14% Debt/Equity Ratio 144.3%
How did NVCR N perform over the long term?
See historical performance and comparison
Company Analysis and Financial Data Status Data Last Updated (UTC time) Company Analysis 2023/12/30 07:56 End of Day Share Price 2023/10/02 00:00 Earnings 2023/09/30 Annual Earnings 2022/12/31
Data Sources The data used in our company analysis is from S&P Global Market Intelligence LLC . The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package Data Timeframe Example US Source * Company Financials 10 years Income statement Cash flow statement Balance sheet Analyst Consensus Estimates +3 years Forecast financials Analyst price targets Market Prices 30 years Stock prices Dividends, Splits and Actions Ownership 10 years Top shareholders Insider trading Management 10 years Leadership team Board of directors Key Developments 10 years
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here .
Analysis Model and Snowflake Details of the analysis model used to generate this report is available on our Github page , we also have guides on how to use our reports and tutorials on Youtube .
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources NovoCure Limited is covered by 14 analysts. 7 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst Institution Gregory Gilbert Deutsche Bank Vijay Kumar Evercore ISI Emily Bodnar H.C. Wainwright & Co.
Show 11 more analysts 